Bianca B. Ruzicka

934 total citations
22 papers, 787 citations indexed

About

Bianca B. Ruzicka is a scholar working on Cellular and Molecular Neuroscience, Genetics and Molecular Biology. According to data from OpenAlex, Bianca B. Ruzicka has authored 22 papers receiving a total of 787 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cellular and Molecular Neuroscience, 6 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Bianca B. Ruzicka's work include Neuroscience and Neuropharmacology Research (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Neuropeptides and Animal Physiology (6 papers). Bianca B. Ruzicka is often cited by papers focused on Neuroscience and Neuropharmacology Research (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Neuropeptides and Animal Physiology (6 papers). Bianca B. Ruzicka collaborates with scholars based in United States, Canada and Italy. Bianca B. Ruzicka's co-authors include Huda Akil, Barbara Gulanski, Pamela Cyrus, Khem Jhamandas, John Orazem, Florian Bieber, Stanley J. Watson, John C. Morris, Robert C. Thompson and Charles A. Fox and has published in prestigious journals such as Blood, Neurology and Journal of Bone and Joint Surgery.

In The Last Decade

Bianca B. Ruzicka

22 papers receiving 750 citations

Peers

Countries citing papers authored by Bianca B. Ruzicka

Since Specialization

Citations

This map shows the geographic impact of Bianca B. Ruzicka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bianca B. Ruzicka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bianca B. Ruzicka more than expected).

Fields of papers citing papers by Bianca B. Ruzicka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bianca B. Ruzicka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bianca B. Ruzicka. The network helps show where Bianca B. Ruzicka may publish in the future.

Co-authorship network of co-authors of Bianca B. Ruzicka

This figure shows the co-authorship network connecting the top 25 collaborators of Bianca B. Ruzicka. A scholar is included among the top collaborators of Bianca B. Ruzicka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bianca B. Ruzicka. Bianca B. Ruzicka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Retrospective Analysis of the Impact of Adverse Event–Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Shuo Ma, Rebecca J. Chan, Lin Gu, Guan Xing, Nishanthan Rajakumaraswamy, Bianca B. Ruzicka, Nina D. Wagner‐Johnston	11
2	No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib 2020 ·Leukemia & lymphoma ·Jacqueline C. Barrientos, Peter Hillmen, Gilles Salles, Jeff P. Sharman, Stephan Stilgenbauer, (unknown), Guan Xing, Bianca B. Ruzicka, Pankaj Bhargava, Paolo Ghia, John M. Pagel	2
3	Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting 2019 ·Blood ·David Andorsky, Rebecca J. Chan, (unknown), Bianca B. Ruzicka, Nicholas J. Robert, Farrukh T. Awan	2
4	Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia 2019 ·Blood ·Shuo Ma, Rebecca J. Chan, Lin Gu, Guan Xing, (unknown), Bianca B. Ruzicka, Nina D. Wagner‐Johnston	1
5	Survival Outcomes Following Idelalisib Interruption in the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia 2018 ·Blood ·Shuo Ma, Rebecca J. Chan, Wei Ye, Guan Xing, (unknown), (unknown), Bianca B. Ruzicka, Nina D. Wagner‐Johnston	3
6	Aprotinin Decreases Exposure to Allogeneic Blood During Primary Unilateral Total Hip Replacement* 2000 ·Journal of Bone and Joint Surgery ·John M. Murkin, George M. Haig, (unknown), Nicholas Cicutti, JOHN W. MCCUTCHEN, (unknown), Richard Hall, Bianca B. Ruzicka	64
7	The Effects of Metrifonate on the Cognitive, Behavioral, and Functional Performance of Alzheimer's Disease Patients 1999 ·The Journal of Clinical Psychiatry ·Murray A. Raskind, Pamela Cyrus, Bianca B. Ruzicka, Barbara Gulanski, (unknown)	82
8	Pharmacokinetics, Pharmacodynamics, and Safety of Metrifonate in Patients with Alzheimer's Disease 1998 ·The Journal of Clinical Pharmacology ·L. Creed Pettigrew, Florian Bieber, John Lettieri, Daniel P. Wermeling, Frederick A. Schmitt, (unknown), J. Wesson Ashford, Charles D. Smith, David R. Wekstein, William R. Markesbery, John Orazem, Bianca B. Ruzicka, (unknown), Barbara Gulanski	48
9	Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease 1998 ·Neurology ·John C. Morris, Pamela Cyrus, John Orazem, (unknown), Florian Bieber, Bianca B. Ruzicka, Barbara Gulanski	228
10	The interleukin-1β-mediated regulation of proenkephalin and opioid receptor messenger RNA in primary astrocyte-enriched cultures 1997 ·Neuroscience ·Bianca B. Ruzicka, Huda Akil	55
11	Interleukin‐1β‐Mediated Regulation of μ‐Opioid Receptor mRNA in Primary Astrocyte‐Enriched Cultures 1996 ·Journal of Neurochemistry ·Bianca B. Ruzicka, Robert C. Thompson, Stanley J. Watson, Huda Akil	57
12	Primary astroglial cultures derived from several rat brain regions differentially express μ, δ and κ opioid receptor mRNA 1995 ·Molecular Brain Research ·Bianca B. Ruzicka, Charles A. Fox, Robert C. Thompson, Fan Meng, Stanley J. Watson, Huda Akil	109
13	Differential Cellular Regulation of Pro-Opiomelanocortin by Interleukin-1-Beta and Corticotropin-Releasing Hormone 1995 ·Neuroendocrinology ·Bianca B. Ruzicka, Huda Akil	12
14	Opioid receptor mRNA expression in primary cultures of glial cells derived from different rat brain regions 1994 ·Regulatory Peptides ·Bianca B. Ruzicka, Charles A. Fox, Robert C. Thompson, Huda Akil, Stanley J. Watson	4
15	Excitatory amino acid action on the release of brain neurotransmitters and neuromodulators: Biochemical studies 1993 ·Progress in Neurobiology ·Bianca B. Ruzicka, Khem Jhamandas	50
16	Quinolinic acid elevates striatal and pallidal met-enkephalin levels: the role of enkephalin synthesis and release 1991 ·Brain Research ·Bianca B. Ruzicka, Richard O. Day, K. Jhamandas	3
17	The K⁺-evoked release of [³H]acetylcholine from slices of rat globus pallidus: modulation by δ-opioid receptors 1991 ·Canadian Journal of Physiology and Pharmacology ·Bianca B. Ruzicka, Khem Jhamandas	3
18	Met-enkephalin release from slices of the rat striatum and globus pallidus: stimulation by excitatory amino acids. 1991 ·Journal of Pharmacology and Experimental Therapeutics ·Bianca B. Ruzicka, K. Jhamandas	23
19	Elevation of met-enkephalin-like immunoreactivity in the rat striatum and globus pallidus following the focal injection of excitotoxins 1990 ·Brain Research ·Bianca B. Ruzicka, Khem Jhamandas	16
20	Depression of potassium-evoked striatal acetylcholine release by δ-receptor activation: inhibition by cholinoactive agents 1988 ·Canadian Journal of Physiology and Pharmacology ·Bianca B. Ruzicka, Khem Jhamandas	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact